Clinical Trial Update: MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating allogeneic hematopoietic stem cell transplantation and serial donor mesenchymal stromal cells for biochemical correction in sev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa

Drugs mentioned

• Allogeneic hematopoietic stem cell transplantation
• Mesenchymal stromal cells (donor-derived)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Epidermolysis Bullosa | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19